Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7171 to 7185 of 8900 results

  1. Customised titanium implants for orofacial reconstruction (IPG28)

    Interventional procedures, IPG28 - Issued: December 2003 --> This guidance has been replaced by NICE HealthTech guidance 313 and NICE HealthTech guidance 307.

    Withdrawn guidance

  2. Sacrocolpopexy using mesh for vaginal vault prolapse repair (IPG283)

    Interventional procedures, IPG283 - Issued: January 2009 --> This guidance has been updated and replaced by NICE interventional procedure guidance 583.

    Withdrawn guidance

  3. Electrically-stimulated intravesical chemotherapy for superficial bladder cancer (IPG277)

    Interventional procedures, IPG277 - Issued: November 2008 --> This guidance has been updated and replaced by NICE interventional procedures guidance 638.

    Withdrawn guidance

  4. Laparoscopic prostatectomy for benign prostatic obstruction (IPG275)

    Interventional procedures, IPG275 - Issued: November 2008 --> We have moved interventional procedures guidance 275 to become HealthTech guidance 176. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  5. Infracoccygeal sacropexy using mesh for uterine prolapse repair (IPG280)

    Interventional procedures, IPG280 - Issued: January 2009 --> This guidance has been updated and replaced by NICE interventional procedures guidance 582.

    Withdrawn guidance

  6. Sacrocolpopexy with hysterectomy using mesh for uterine prolapse repair (IPG284)

    Interventional procedures, IPG284 - Issued: January 2009 --> This guidance has been updated and replaced by NICE interventional procedures guidance 577.

    Withdrawn guidance

  7. Functional electrical stimulation for drop foot of central neurological origin (IPG278)

    Interventional procedures, IPG278 - Issued: January 2009 --> We have moved interventional procedures guidance 278 to become HealthTech guidance 178. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  8. Digital technologies for assessing attention deficit hyperactivity disorder (ADHD) (DG60)

    We have moved Diagnostics guidance 60 to become HealthTech guidance 729. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  9. Home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome (DG62)

    We have moved Diagnostics guidance 62 to become HealthTech guidance 735. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  10. Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer (DG8)

    We have moved Diagnostics guidance 8 to become HealthTech guidance 315. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  11. Heart failure algorithms for remote monitoring in people with cardiac implantable electronic devices (DG61)

    We have moved Diagnostics guidance 61 to become HealthTech guidance 730. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  12. EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer (DG9)

    We have moved Diagnostics guidance 9 to become HealthTech guidance 316. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  13. SeHCAT (tauroselcholic [75 selenium] acid) for the investigation of diarrhoea due to bile acid malabsorption in people with diarrhoea-predominant irritable bowel syndrome (IBS-D) or Crohn's disease without ileal resection (DG7)

    This guidance has been updated and replaced by NICE healthtech guidance 598.

    Withdrawn guidance

  14. KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication: early value assessment (HTE10)

    We have moved health technology evaluation 10 to become HealthTech guidance 694. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  15. Ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections (HTE1)

    We have moved HTE1 to become 'antimicrobial resistance guidance'. This is to better reflect what the purpose of this product is and to help you find relevant content more quickly. The guidance itself has not changed. See antimicrobial resistance guidance 1 on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections.

    Withdrawn guidance